Home Links

Links

MedWatch Safety Alerts RSS Feed
  • E-cigarette: Safety Communication - Related to Seizures Reported Following E-cigarette Use, Particularly in Youth and Young Adults

    Safety Communication - Related to Seizures Reported Following E-cigarette Use, Particularly in Youth and Young Adults [ Read more ]
  • Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines

    FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain NDMA. [ Read more ]
  • Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose

    Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose [ Read more ]
  • Tetrahydrocannabinol (THC)-containing Vaping Products: Vaping Illnesses

    Consumers are likely aware of the recent reports of respiratory illnesses – including some resulting in deaths – following the use of vaping products.The FDA is working closely with the CDC, as well as state and local public health partners to investigate them as quickly as possible. [ Read more ]
  • Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib): Drug Safety Communication - Due to Rare but Severe Lung Inflammation

    FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs. [ Read more ]
  • E-Cigarette Products: Safety Communication - Due to the Incidents of Severe Respiratory Disease Associated with Use of an E-Cigarette Product

    Both the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention are working tirelessly to investigate the distressing incidents of severe respiratory disease associated with use of e-cigarette products. [ Read more ]
  • Fecal Microbiota for Transplantation: Safety Communication- Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms

    FDA MedWatch Alert regarding Fecal Microbiota for Transplantation: Safety Communication- Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms [ Read more ]
  • Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease

    FDA has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic Hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure. [ Read more ]
  • Certain Prescription Insomnia Medicines: New Boxed Warning - Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake

    MedWatch Alert on certain prescription insomnia medicines. [ Read more ]
FDA Press Releases RSS Feed
  • Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications

    The FDA is issuing an update regarding the ongoing efforts to resolve safety issues with ARB medications. [ Read more ]
  • FDA statement on court ruling related to compounded bulk drug substances and the agency’s ongoing efforts to implement its compounding authorities

    A U.S. District Court judge in Washington, D.C. issued a decision that upheld FDA’s interpretation of clinical need regarding the bulk substances that may be used by outsourcing facilities in drug compounding. [ Read more ]
  • Trump Administration Combating Epidemic of Youth E-Cigarette Use with Plan to Clear Market of Unauthorized, Non-Tobacco-Flavored E-Cigarette Products

    : FDA intends to finalize compliance policy that would prioritize enforcement of premarket authorization requirements for non-tobacco-flavored e-cigarettes, clearing the market these products. [ Read more ]
  • FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease

    FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease [ Read more ]
  • FDA proposes new required health warnings with color images for cigarette packages and advertisements to promote greater public understanding of negative health consequences of smoking

    FDA has issued a proposed rule to require new health warnings on cigarette packages and in ads to promote greater public understanding of the negative health consequences of smoking. [ Read more ]
  • FDA warns consumers about the dangerous and potentially life threatening side effects of Miracle Mineral Solution

    The FDA is warning consumers not to purchase or drink Miracle Mineral Solution, a product sold online as a medical treatment due to a recent rise in reported health issues. [ Read more ]
  • FDA warns company for putting consumers at risk with drug manufacturing data integrity violations

    The FDA posted a warning letter for significant current good manufacturing practice violations, including data integrity issues. [ Read more ]
  • FDA sends warning to company for selling unapproved umbilical cord blood and umbilical cord products that may put patients at risk; continues to warn patients of the risk of unapproved stem cell therapy

    : FDA sends warning to company for selling unapproved umbilical cord blood and umbilical cord products that may put patients at risk; continues to warn patients of the risk of unapproved stem cell therapy [ Read more ]
  • FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery

    FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery. [ Read more ]
  • Statement alerting patients and health care professionals of NDMA found in samples of ranitidine

    The U.S. Food and Drug Administration has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. [ Read more ]
  • FDA approves new antibiotic to treat community-acquired bacterial pneumonia

    The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. [ Read more ]
  • Statement on improving adverse event reporting of compounded drugs to protect patients

    The FDA is working to improve adverse event reporting of compounded drugs to protect patients [ Read more ]
  • FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety

    FDA has issued a warning letter to Curaleaf Inc. for illegally selling unapproved cannabidiol products online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases. [ Read more ]
  • Statement on federal and state collaboration to investigate respiratory illnesses reported after use of e-cigarette products

    FDA and CDC are providing updates about federal and state efforts to investigate respiratory illnesses reported after the use of e-cigarette products. [ Read more ]
  • FDA approves first therapy for rare joint tumor

    FDA approves first therapy for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) [ Read more ]
Food and Drugs Administration--Recalls/Safety Alerts
  • Udi’s Classic Hamburger Buns Recalled due to Potential Presence of Foreign Material

    Conagra Brands is voluntarily recalling a limited quantity (approx. 2,200 cases) of Udi’s Classic Hamburger Buns due to the potential presence of small pieces of white plastic. [ Read more ]
  • Hy-Vee Voluntarily Recalls Several Hy-Vee Mealtime Asian Entrees Due to Undeclared Milk Allergen

    Hy-Vee, Inc., based in West Des Moines, Iowa, is voluntarily recalling seven of its Hy-Vee Mealtime Asian Entrees after discovering the liquid egg used to make the fried rice contains milk, which is not declared on the product label. [ Read more ]
  • KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

    KRS Global Biotechnology, Inc. is voluntarily recalling all lots of unexpired human and animal drugs intended to be sterile to the consumer level. The products are being recalled due to lack of assurance of sterility. [ Read more ]
  • Dog Goods USA LLC Expands Voluntary Recall of Chef Toby Pig Ears Pet Treats Because of Possible Salmonella Health Risk on 9/3/2019

    Dog Goods is voluntarily expanding this recall to include all 30-packs of "Berkley & Jensen" brand pig ears sold at BJ's Wholesale Club stores. Dog Goods purchased these pig ears from a single supplier in Brazil from September 2018 through August 2019. [ Read more ]
  • KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

    KRS Global Biotechnology, Inc. is voluntarily recalling all lots of unexpired human and animal drugs intended to be sterile to the consumer level. The products are being recalled due to lack of assurance of sterility. [ Read more ]
  • Hometown Food Company Issues Voluntary Recall of Martha White Gluten Free Sweet Cornbread Muffin Mix Due to Possible Presence of Gluten

    Hometown Food Company today initiated a limited, voluntary, consumer-level recall of approximately 374 cases of two specific lot codes of its Martha White Gluten Free Sweet Cornbread Muffin Mix, due to standard quality batch testing that indicated the presence of gluten derived from wheat, rye [ Read more ]
  • Urban Remedy Voluntarily Recalls 76 Salads, Wraps That May Contain E.Coli Bacteria No Illnesses Reported, Company Taking Preventive Action

    Urban Remedy, a California-based producer and retailer of ultra-fresh, organic meals, is voluntarily recalling 76 salads and wraps that contain spinach that may be contaminated with E. coli. Seventy-six salads and wraps are still unaccounted for. No juices or any other products are being recalled. [ Read more ]
  • Great One Trading Inc. Issues Expanding Allergy Alert on Undeclared Egg In Fishball Products

    Great One Trading Inc. is recalling the above because it may contain undeclared egg. People who have an allergy or severe sensitivity to egg run the risk of serious or life-threatening allergic reaction if they consume these products. [ Read more ]
  • Rong Shing Issues Allergy Alert on Undeclared Eggs and Milk in FuPaiYuan Nougat Candies

    RONG SHING of Brooklyn, NY is recalling its 450g packages of FuPaiYuan Nougat candy because they may contain undeclared eggs and milk allergens [ Read more ]
  • Darmerica LLC Issues Voluntary Nationwide Recall of Quinacrine Dihydrochloride Due to A Labeling Error

    Darmerica LLC is voluntarily recalling two lots, DR4654A and DL4654A, of Quinacrine Dihydrochloride, bulk API powder packaged in Amber HDPE Bottles to the consumer level. This product is being recalled due to a label mix-up. Product intended for further compounding use by pharmacies labeled as Quin [ Read more ]
  • Rong Shing Issues Allergy Alert on Undeclared Eggs and Milk in FuPaiYuan Matcha Candies

    RONG SHING of Brooklyn, NY is recalling its 450g packages of FuPaiYuan Matcha candy because they may contain undeclared eggs and milk allergens [ Read more ]
  • The Metrix Company of Dubuque, Iowa is Recalling Specific Lots of the Empty IV Flexible Containers (Bag) Marketed Under the Metrix Secure EVA Dual Chamber and Baxter ExactaMix Names, Due to the Potential for Leaking of the IV Bag at the Chamber Divider Rod

    The Metrix Company of Dubuque, Iowa is recalling specific lots of the empty IV flexible containers (bag) marketed under the Metrix Secure EVA Dual Chamber and Baxter ExactaMix names, due to the potential for leaking of the IV bag at the chamber divider rod, which could result in a serious infection [ Read more ]
  • Stark Group International Issues Allergy Alert on Undeclared Milk Allergens in Ritter Sport KAFFEESPLITTER - 3.5 Ounce /100 Gram

    Stark Group International of Greenvale, NY is recalling all codes of its 100 gram packages of Ritter Sport -KAFFEESPLITTER because they may contain undeclared milk allergens. [ Read more ]
  • Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension 2400 mg/30 mL due to Microbial Contamination

    Plastikon Healthcare, LLC isvoluntarily recalling Milk of Magnesia 2400 mg/30 mL Oral Suspension, lots 19027D and 19027E, to the patient level. Plastikon Healthcare initiated this recall because these product lots did not meet Plastikon’s in-house microbiological specification for Total Aerobic Mic [ Read more ]
  • House Of Spices (India) Issues Recall of "MDH Sambar Masala" Due To Salmonella Contamination

    House of Spices (India) is recalling different lots of “MDH SAMBAR MASALA”, 3.5oz (100g) UPC code 6291103750327.This product is produced by R-PURE AGRO SPECIALITIES and distributed by HOUSE OF SPICES (INDIA). This product was tested by FDA through a certified laboratory to be positive for Salmonella [ Read more ]
Twitter Search / FDADeviceInfo
Twitter feed for: FDADeviceInfo. Generated by TwitRSS.me
  • Update #2: “Refuse to Accept Policy for 510(k)s” Final Guidance: https://go.usa.gov/xVnGB 

    Update #2: “Refuse to Accept Policy for 510(k)s” Final Guidance: https://go.usa.gov/xVnGB  [ Read more ]
  • Update #1 “Format for Traditional and Abbreviated (510(k)s)” Final Guidance: https://go.usa.gov/xVnGZ 

    Update #1 “Format for Traditional and Abbreviated (510(k)s)” Final Guidance: https://go.usa.gov/xVnGZ  [ Read more ]
  • In an effort to improve alignment between the related 510(k) guidance, and reflect current policies, the @US_FDA also updated two related guidance documents:

    In an effort to improve alignment between the related 510(k) guidance, and reflect current policies, the @US_FDA also updated two related guidance documents: [ Read more ]
  • The @US_FDA also issued a final guidance on The Abbreviated 510(k) Program. Together, these guidance documents will superseded “The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications” guidance: https://go.usa.gov/xVnGT pic.twitter.com/NbRqWru8kB

    The @US_FDA also issued a final guidance on The Abbreviated 510(k) Program. Together, these guidance documents will superseded “The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications” guidance: https://go.usa.gov/xVnGT  pic.twitter.com/NbRqWru8kB [ Read more ]
  • Learn more about the Special 510(k) Program guidance: https://go.usa.gov/xVnGq 

    Learn more about the Special 510(k) Program guidance: https://go.usa.gov/xVnGq  [ Read more ]
  • Today, the @ US_FDA issued final guidance on The Special 510(k) Program. The program is an optional regulatory pathway that simplifies the review of certain 510(k)s for industry and FDA staff using efficient practices consistent with least burdensome principles.pic.twitter.com/eryJzqVssl

    Today, the @ US_FDA issued final guidance on The Special 510(k) Program. The program is an optional regulatory pathway that simplifies the review of certain 510(k)s for industry and FDA staff using efficient practices consistent with least burdensome principles. pic.twitter.com/eryJzqVssl [ Read more ]
  • #DYK: The Office of Science and Engineering Laboratories here at @US_FDA promotes the innovation of newer, safer and more effective medical devices? Check out what's been happening here at OSEL: https://youtube.com/watch?v=m-73PWZjIXI … #FDA #MedicalDevice

    #DYK: The Office of Science and Engineering Laboratories here at @US_FDA promotes the innovation of newer, safer and more effective medical devices? Check out what's been happening here at OSEL: https://youtube.com/watch?v=m-73PWZjIXI … #FDA #MedicalDevice [ Read more ]
  • FDA reminds the public that no youth should be using any vaping product, regardless of the substance being inhaled. As kids head #BacktoSchool – a place where they vape or see their peers vape – “The Real Cost” campaign strives to help prevent youth e-cigarette use. THREAD pic.twitter.com/GMl2RyMvaS

    FDA reminds the public that no youth should be using any vaping product, regardless of the substance being inhaled. As kids head #BacktoSchool – a place where they vape or see their peers vape – “The Real Cost” campaign strives to help prevent youth e-cigarette use. THREAD pic.twitter.com/GMl2RyMvaS [ Read more ]
  • Thank you to everyone who participated in today’s #PEAC2019 meeting. Everyone provided thoughtful discussion and recommendations for the @US_FDA to consider when communicating cybersecurity risks. A summary of the meeting will be available at https://go.usa.gov/xVNvv 

    Thank you to everyone who participated in today’s #PEAC2019 meeting. Everyone provided thoughtful discussion and recommendations for the @US_FDA to consider when communicating cybersecurity risks. A summary of the meeting will be available at https://go.usa.gov/xVNvv  [ Read more ]
  • Manufacturers should be responsible for educating not only the providers, but the patients receiving their device. Discussion at #PEAC2019

    Manufacturers should be responsible for educating not only the providers, but the patients receiving their device. Discussion at #PEAC2019 [ Read more ]
  • How much information you can provide is very individual to the type of device a person has & how it impacts them. There is no substitute for talking to patients w/in a community of patients w/ a specific disease/device, as they are experts in this area. Discussion at #PEAC2019

    How much information you can provide is very individual to the type of device a person has & how it impacts them. There is no substitute for talking to patients w/in a community of patients w/ a specific disease/device, as they are experts in this area. Discussion at #PEAC2019 [ Read more ]
  • It is critical when communicating cybersecurity information to hear from the patient community about what information they want and how they want to receive it. Advisory Committee Discussion at #PEAC2019

    It is critical when communicating cybersecurity information to hear from the patient community about what information they want and how they want to receive it. Advisory Committee Discussion at #PEAC2019 [ Read more ]
  • Medical device technicians should have training on cybersecurity. Physicians should focus on care and defer the technical expertise. Committee discussion on FDA questions about communicating cybersecurity today at #PEAC2019

    Medical device technicians should have training on cybersecurity. Physicians should focus on care and defer the technical expertise. Committee discussion on FDA questions about communicating cybersecurity today at #PEAC2019 [ Read more ]
  • "...I would want to know 1. What I need to do to mitigate the risks and 2. And what do I do if I feel I believe I have been impacted.” Patient during public open hearing at #PEAC2019

    "...I would want to know 1. What I need to do to mitigate the risks and 2. And what do I do if I feel I believe I have been impacted.” Patient during public open hearing at #PEAC2019 [ Read more ]
  • “I would prefer my first communication come through as a text message from my doctor’s office that tells me to call my doctor..."

    “I would prefer my first communication come through as a text message from my doctor’s office that tells me to call my doctor..." [ Read more ]
What's New: Drugs RSS Feed
  • Dermatologic and Ophthalmic Drugs Advisory Committee Roster

    This page contains the DODAC roster, which lists the current members and the current number of vacancies for the committee. [ Read more ]
  • Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines

    FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain NDMA. [ Read more ]
  • What's New Related to Drugs

    Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc. [ Read more ]
  • Meetings, Conferences, & Workshops (Drugs)

    Drugs-Related Meetings [ Read more ]
  • Recalls of Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan

    Get current information about recalls of blood pressure medications [ Read more ]
  • Drug Trials Snapshots

    Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent. Drug Trials Snapshots provide consumers with information about who participated in clinical trials that supported the FDA approval of new drugs. The information provided in these Snapshots also highlights whether there were any differences in the benefits and side effects among sex, race and age groups. [ Read more ]
  • FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)

    Updates and Press Announcements regarding NDMA in Zantac (ranitidine) medicines. [ Read more ]
  • KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

    KRS Global Biotechnology, Inc. is voluntarily recalling all lots of unexpired human and animal drugs intended to be sterile to the consumer level. The products are being recalled due to lack of assurance of sterility. [ Read more ]
  • FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)

    Get updates on the recalls [ Read more ]
  • Darmerica LLC Issues Voluntary Nationwide Recall of Quinacrine Dihydrochloride Due to A Labeling Error

    Darmerica LLC is voluntarily recalling two lots, DR4654A and DL4654A, of Quinacrine Dihydrochloride, bulk API powder packaged in Amber HDPE Bottles to the consumer level. This product is being recalled due to a label mix-up. Product intended for further compounding use by pharmacies labeled as Quin [ Read more ]
  • Recently Issued Guidance Documents

    This page lists Recently Issued CBER and Cross-Center Guidance Documents. [ Read more ]
  • Compounding: Inspections, Recalls, and other Actions

    Human drug compounding; FDA inspections; compounding recalls [ Read more ]
  • 2019 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee

    This page contains the meeting materials for the Endocrinologic and Metabolic Advisory Committee meetings for 2019, including the meeting announcement, briefing materials, committee roster, webcast information, agenda, committee questions, meeting roster, presentation slides, etc. [ Read more ]
  • Drug Trials Snapshots: ROZLYTREK

    ROZLYTREK is a drug used to treat adult and adolescent patients (12 to 17 years old) whose cancers have a specific genetic feature (biomarker) [ Read more ]
  • November 14, 2019: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement - 11/14/2019 - 11/14/2019

    November 14, 2019: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement [ Read more ]
Whats New Vaccines Blood Biologics RSS Feed
  • Cleared 510(k) Submissions with Supporting Documents

    Listing of cleared 510(k) submissions with supporting documents. Information is reflected as of the clearance date. [ Read more ]
  • Format for Traditional and Abbreviated 510(k)s

    This guidance provides instruction on how to format a Traditional or Abbreviated 510(k). [ Read more ]
  • Devices Guidances

    This page lists Medical Device Guidance documents. [ Read more ]
  • Statement on data accuracy issues with recently approved gene therapy

    Statement by Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research, on data accuracy issues with recently approved gene therapy [ Read more ]
  • Recently Issued Guidance Documents

    This page lists Recently Issued CBER and Cross-Center Guidance Documents. [ Read more ]
  • The Special 510(k) Program

    This guidance provides the framework that FDA uses when considering whether a 510(k) is appropriate for review as a Special 510(k). [ Read more ]
  • Select CBER Projects and Activities

    CBER projects and activities that address the 21st Century Cures Act and the Prescription Drug User Fees Act VI Reauthorization (PDUFA VI) as authorized by the FDA Reauthorization Act (FDARA) [ Read more ]
  • 2019 Scientific Computing Days Symposium - 09/09/2019 - 09/10/2019

    The 2019 Scientific Computing Days symposium will boast a plethora of scientists, key industry contributors, gathering to help the FDA improve the application of technology, and scientific computing in support of FDA’s public health mission [ Read more ]
  • MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    MedWatch home page [ Read more ]
  • What’s New for Biologics

    Latest news from the Center for Biologics Evaluation and Research [ Read more ]
  • Field Science - Laboratory Manual

    The Laboratory Manual is a reference manual for FDA personnel. It provides FDA personnel with information on internal procedures to be used as an agency policy for testing consumer products, training of laboratory staff, report writing, safety, research, review of private laboratory reports and cour [ Read more ]
  • Refuse to Accept Policy for 510(k)s

    Procedures and criteria used in assessing whether a 510(k) submission meets minimum threshold of acceptability and should be accepted for substantive review. [ Read more ]
  • International Activities

    CBER’s international activities can be categorized in the following functional areas: regulatory harmonization, regulatory capacity building, information sharing, international standards setting, and collaborative research. [ Read more ]
  • Stratus BioSystems, LLC - 581032 - 07/01/2019

    Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps) [ Read more ]
  • Safety & Availability (Biologics)

    Important information about the safety and availability of biological products. [ Read more ]

News & Events

  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>
  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>